Lang et al., 2021 - Google Patents
First-line pembrolizumab mono-or combination therapy of non-small cell lung cancer: baseline metabolic biomarkers predict outcomesLang et al., 2021
View HTML- Document ID
- 8206008535484835283
- Author
- Lang D
- Ritzberger L
- Rambousek V
- Horner A
- Wass R
- Akbari K
- Kaiser B
- Kronbichler J
- Lamprecht B
- Gabriel M
- Publication year
- Publication venue
- Cancers
External Links
Snippet
Simple Summary Positron-emission tomography/computed tomography (PET/CT) is used for staging of non-small cell lung cancer (NSCLC) and can help to estimate prognosis in patients treated with immune checkpoint inhibitor (ICI) therapy. Most available data in that …
- 208000002154 Non-Small-Cell Lung Carcinoma 0 title abstract description 86
Classifications
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G06Q50/10—Services
- G06Q50/22—Health care, e.g. hospitals; Social work
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
- G06F19/32—Medical data management, e.g. systems or protocols for archival or communication of medical images, computerised patient records or computerised general medical references
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
- G06F19/34—Computer-assisted medical diagnosis or treatment, e.g. computerised prescription or delivery of medication or diets, computerised local control of medical devices, medical expert systems or telemedicine
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G06Q50/01—Social networking
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hashimoto et al. | Potential of FDG-PET as prognostic significance after anti-PD-1 antibody against patients with previously treated non-small cell lung cancer | |
Monaco et al. | Metabolic parameters as biomarkers of response to immunotherapy and prognosis in non-small cell lung cancer (NSCLC): a real world experience | |
Lang et al. | First-line pembrolizumab mono-or combination therapy of non-small cell lung cancer: baseline metabolic biomarkers predict outcomes | |
Palumbo et al. | Prediction of early distant recurrence in upfront resectable pancreatic adenocarcinoma: a multidisciplinary, machine learning-based approach | |
Bouron et al. | Prognostic value of metabolic, volumetric and textural parameters of baseline [18F] FDG PET/CT in early triple-negative breast cancer | |
Zhou et al. | 18F-FDG, 11C-methionine, and 68Ga-Pentixafor PET/CT in patients with smoldering multiple myeloma: imaging pattern and clinical features | |
Lee et al. | Prognostic impact of perioperative CA19-9 levels in patients with resected perihilar cholangiocarcinoma | |
Kim et al. | Prognostic role of pre-treatment [18F] FDG PET/CT in patients with anaplastic thyroid cancer | |
Mendoza-Moreno et al. | Prognostic factors of survival in patients with peritoneal metastasis from colorectal cancer | |
Dumas et al. | The French Early Breast Cancer Cohort (FRESH): a resource for breast cancer research and evaluations of oncology practices based on the French National Healthcare System Database (SNDS) | |
Vivaldi et al. | Early tumor shrinkage and depth of response evaluation in metastatic pancreatic cancer treated with first line chemotherapy: an observational retrospective cohort study | |
Laudicella et al. | Preliminary findings of the role of FAPi in prostate cancer theranostics | |
Mataki et al. | Clinical benefits of conversion surgery for unresectable pancreatic ductal adenocarcinoma: A single-institution, retrospective analysis | |
Fosbøl et al. | uPAR PET/CT for prognostication and response assessment in patients with metastatic castration-resistant prostate cancer undergoing radium-223 therapy: A prospective phase II study | |
Agostinetto et al. | Post-neoadjuvant treatment strategies for patients with early breast cancer | |
Shin et al. | The Clinical Implication of Conversion Surgery in Patients with Stage IV Gastric Cancer Who Received Systemic Chemotherapy | |
Lee et al. | Prognostic impact of total lesion glycolysis (TLG) from preoperative 18F-FDG PET/CT in stage II/III colorectal adenocarcinoma: extending the value of PET/CT for resectable disease | |
Lee et al. | Muscle characteristics obtained using computed tomography as prognosticators in patients with castration-resistant prostate cancer | |
Rogé et al. | Different prognostic values of tumour and nodal response to neoadjuvant chemotherapy depending on subtypes of inflammatory breast cancer, a 317 patient-study | |
Park et al. | Relationship between systemic inflammatory markers, GLUT1 expression, and Maximum 18F-Fluorodeoxyglucose Uptake in Non-small Cell Lung Carcinoma and their prognostic significance | |
Oriuchi et al. | Monitoring of current cancer therapy by positron emission tomography and possible role of radiomics assessment | |
Sirico et al. | Early changes of the standardized uptake values (SUVmax) predict the efficacy of everolimus-exemestane in patients with hormone receptor-positive metastatic breast cancer | |
Lee et al. | Dual-time-point FDG uptake correlates with prognostic factors of invasive breast cancer: Clinical usefulness of early delayed scanning | |
Kang et al. | Complete and durable response to nivolumab in recurrent poorly differentiated pancreatic neuroendocrine carcinoma with high tumor mutational burden | |
Nakane et al. | Trends in the Use of Second-Generation Androgen Receptor Axis Inhibitors for Metastatic Hormone-Sensitive Prostate Cancer and Clinical Factors Predicting Biological Recurrence |